Managing Cutaneous Side Effects From Targeted Molecular Inhibitors for Melanoma and Nonmelanoma Skin Cancer
| Autor: | Desiree Ratner, Nikki Tang |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Oncology
medicine.medical_specialty Skin Neoplasms medicine.drug_class Ipilimumab Antineoplastic Agents Dermatology Pembrolizumab Skin Diseases Tyrosine-kinase inhibitor 030207 dermatology & venereal diseases 03 medical and health sciences 0302 clinical medicine Internal medicine medicine Humans Molecular Targeted Therapy Vemurafenib Melanoma Trametinib Cetuximab business.industry Dabrafenib General Medicine medicine.disease 030220 oncology & carcinogenesis Surgery Skin cancer business medicine.drug |
| Zdroj: | Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]. 42 |
| ISSN: | 1524-4725 |
| Popis: | Background Targeted anticancer therapies can cause cutaneous adverse events different from classical chemotherapeutic toxicities. Objective To review the literature on dermatologic adverse events (DAEs) of targeted molecular inhibitors for melanoma and nonmelanoma skin cancers with a focus on management options. Materials and methods A comprehensive literature search related to the side effects and management of these side effects from vemurafenib, dabrafenib, trametinib (BRAF inhibitors), pembrolizumab (antiprogrammed-death-receptor-1 antibody), imatinib (tyrosine kinase inhibitor), ipilimumab (anticytotoxic T-lymphocyte antigen-4 antibody), cetuximab (epidermal growth factor receptor inhibitor), sorafenib (multikinase inhibitor), and vismodegib (smoothened receptor inhibitor). Results No large controlled studies specifically examining the management of DAEs of targeted molecular inhibitors exist, although there are case report-based recommendations and algorithms developed by expert panels to manage these adverse events. Conclusion Many options for managing the cutaneous side effects of targeted molecular inhibitors are similar to those used in general dermatology practice. When used effectively, drug dosing and patient quality of life may be optimized. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|